Reprocell buys into cell therapy discovery services sector with Biopta takeover

By Gareth Macdonald

- Last updated on GMT

Reprocell buys Biopta for preclinical services business
Reprocell buys Biopta for preclinical services business

Related tags Stem cell

Reprocell has entered the CRO space through the acquisition of preclinical discovery services Biopta.

The Japanese stem cell specialist said the takeover - financial terms of which have not been disclosed – will be followed by an investment to expand the range of services offered by Biopta at its facilities in Glasgow, Scotland and Maryland, US.

Biopta's core focus is using human tissues to assess the toxicity of drug candidates, which it claims provides a more prediction than traditional animal models.

Pharmaceutical industry demand for such services is growing according to Reprocell, which said the high cost and time it takes to complete assessments in animal models has prompted sponsors to look for alternatives.

Prior to the acquisition ReproCell’s focus was the development and production of reagents, cells and reprogramming kits for companies developing induced pluripotent stem cell (iPS) based therapeutics.

The Japanese firm said: “With our acquisition of Biopta and the addition of new drug discovery support services to our business line-up, we are able to offer both our main business of the supply of products to pharmaceutical manufacturers, as well as research outsourcing services​.”

Reprocell did not outline any target markets, however, policies introduced in November 2013 by the Japanese Government to boost cell and regenerative therapy development​ may provide the firm with a potential customer base.

UK connection

The Biopta deal also connects Reprocell to a UK network of specialist contractors with which Biopta partnered in February​ this year.

The network – which in addition to Biopta includes Molecular Profiles, XenoGesis, Aurelia BioScience, Reach Separations, Charnwood Molecular – was established to provide sponsors with contractors for each stage of the drug development process.

Related topics Bio Developments Bio-Outsourcing

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars